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Nanoelectrode ensembles (NEEs) are new nanoelectrochemi-
cal tools very useful for electroanalysis and sensors (Menon and
Martin, 1995; Ugo et al., 2002). They are prepared by electroless
deposition of gold within the pores of track-etch polycarbon-
ate membranes. A NEE is made by a very large number of very
small ultramicroelectrodes conﬁned in a rather small space, with
a density ≥108 electrodes/cm2. NEEs can exhibit distinct voltam-
metric response regimes depending on the scan rate or distance
between the nanoelectrode elements. The total overlap regime
is commonly observed at ensembles of nanodisk electrodes pre-
pared from commercial track-etched membranes. Under these
conditions, the faradaic current (signal) is proportional to the geo-
metric area (Ageom; area of nanodisks and polycarbonate), while
the double-layer capacitive current (background) depends on the
active area (Aact; area of the nanodisks). Therefore, NEEs are char-
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doi:10.1016/j.bios.2008.02.027he possibility to prepare highly sensitive nanostructured electrochemical
g biorecognition elements on nanoelectrode ensembles (NEEs) prepared
mbranes. The gold nanodisk electrodes act as electrochemical transduc-
carbonate binds the antibody-based biorecognition layer. The interaction
tibody is detected by suitable secondary antibodies labelled with a redox
ed to the sample solution, shuttles electrons from the nanoelectrodes to
erating an electrocatalytic signal. This allows one to fully exploit the highly
current ratio, typical of NEEs. In particular, the receptor protein HER2was
ER2 detection allows the identiﬁcation of breast cancer that can be treated
trastuzumab. NEEs were functionalized with trastuzumab which interacts
recognition process was completed by adding a primary antibody and a
ith horseradish peroxidase. Hydrogen peroxide was added to modulate
lene blue was the redox mediator generating voltammetric signals. NEEs
b were tested to detect small amounts of HER2 in diluted cell lysates and
© 2008 Elsevier B.V. All rights reserved.acterized by detection limits two to three orders of magnitude
lower than regular electrodes (Ugo et al., 1996; Brunetti et al.,
2000).
In typical schemes used for electrochemical biosensors, a
biorecognition layer is immobilized directly on the electrode sur-
face and the signal is produced by exchange of electrons with
the underlying electrode; this was applied also to arrays of nano-
electrodes (Lin et al., 2004; Li et al., 2003; Lapierre-Devlin et
al., 2005; Delvaux et al., 2005). However, for extremely minia-
turized electrodes, such as NEEs, the amount of biomolecule
immobilized on the nanoelectrodes can be too small to furnish
useful signals (De Leo et al., 2007a). In order to increase the
electrode area available for the immobilization, the templatemem-
brane can be etched (Yu et al., 2003; Lapierre-Devlin et al., 2005;
Krishnamoorthy and Zoski, 2005) to obtain ensembles of gold
nanoﬁbers. However, this causes the increase of capacitive current
and lowering of signal-to-background current ratios (De Leo et al.,
2007a).
This prompted us to explore a different approach, using the
template membrane of the ensemble and not the nanoelectrodes
to immobilize the biorecognition elements. In such a design no
d Bioe
Western blot analysis using a CB11 antibody.
Breast cancer samples were kindly provided by the Department
of Biomedical Sciences and Human Oncology of the University of
Turin, Italy. Sampleswere homogenized using amechanical system
(UltraTurrax T25, Rose Scientiﬁc Ltd., Canada) in the same buffer of
cells, and analysed by Western blot to visualize the expression of
HER2. HER2 concentration was estimated 1ng/l.
3. Results and discussion
Preliminary tests in solution showed that thebestmediator suit-
able to shuttle electron from NEE to HRP is MB.
The dotted line cyclic voltammetry (CV) in Fig. 1, shows a
well-resolved reduction peak recorded at a NEE, relevant to the
reversible reduction (Ye and Baldwin, 1988):
MB + 2e + H+ LB (1)
where LB is the leuco (reduced) form of MB.
MB signals are signiﬁcantly better resolved from background
currents at a NEE than at a conventional Au-electrode, under the
same experimental conditions (not shown).S.P. Mucelli et al. / Biosensors an
increase in Aact is required and voltammetric signals should be
produced at the highest signal/background current ratio.
On the basis of its popularity in classical ELISA tests as well as in
advanced electrochemical immunoassays (Yu et al., 2006)we chose
horseradish peroxidase (HRP) as the enzyme label, using methy-
lene blue (MB) as the redox mediator (in the solution phase) to
shuttle electrons from the nanoelectrodes to the label. We tested
this approachwith an extremely actual issue that is the determina-
tion of the expression levels of the HER2 receptor and the binding
activity of its agonist trastuzumab (or Herceptin®), a drug used in
the adjuvant therapy of the breast cancer (Molina et al., 2001). The
possibility to detect HER2 is extremely important for the identiﬁ-
cation of cancers that can be treated with Herceptin®, providing a
good opportunity to deﬁne the so-called personalized therapies.
2. Materials and methods
2.1. Electrochemical apparatus
All electroanalytical measurements were carried out at room
temperature (22±1 ◦C) with a CH660A potentiostat, using a three-
electrode single-compartment cell equipped with a platinum
counter electrode and an Ag/AgCl (KCl-saturated) reference elec-
trode.
2.2. Chemicals
All chemicals used were reagent grade and used without fur-
ther puriﬁcation. HRP type VI, 298purpurogallin units/mg solid,
was from Sigma. Puriﬁed water was obtained using a Milli-Ro plus
Milli-Q (Millipore) system.
2.3. Sensors
NEEs were prepared by template gold electroless deposition
(Ugo and Moretto, 2007), using recently described updates (De
Leo et al., 2007a,b). Templating membranes were polycarbon-
ate track-etched membranes (SPI-pore, 47mm ﬁlter diameter,
6m thickness) with a nominal pore diameter of 30nm, aver-
age pore density 6×108 pore/cm2, coated by the producer with
polyvinylpyrrolidone. The ﬁnal NEEswere assembled as previously
described (Ugo andMoretto, 2007). A hole punched in an insulating
layer of plastics (Monokote by Topﬂite) determined the Ageom, typ-
ically 0.07 cm2. The value of Aact, estimated by SEM analysis, was
0.001 cm2.
Thedetection strategy is summarizedas follows.Atﬁrst, the spe-
ciﬁc antibody trastuzumab is immobilized on the polycarbonate.
Then, it is incubated with the sample to capture the target pro-
tein HER2. Finally, the captured protein is reactedwith the primary
antibody (namely, monoclonal CB-11) and the secondary labelled
antibody, i.e. anti-mouse HRP-conjugated antibody. Electrochem-
ical signal is generated by MB added as soluble mediator which
shuttles electrons from the nanoelectrode to HRP, when the latter
reacts with its substrate, typically, 1.5mM H2O2.
Trastuzumab functionalized NEEs (T-NEEs) were prepared by
incubating on the NEE 2l of 0.5g/l trastuzumab (Hercerptin®,
Genentech, South San Francisco, CA) in carbonate buffer, for 2h
at 4 ◦C. Polycarbonate contains carbonyl groups which can react
with amine groups of proteins (Rucker et al., 2005). After wash-
ing with phosphate buffer saline, added with 0.2% (v/v) Tween 20
(PBST), and ﬁnal incubation for 10min in NaBH4 to block reactive
groups remaining eventually on the membrane (Afanassiev et al.,
2000), the T-NEE was ready to react with the target analyte. For
capture tests 10l of four dilutions of a 10g/l SKBR3 lysate
(diluted 1:1, 1:5, 1:10, 1:50) were incubated on the T-NEE for 4h atlectronics 23 (2008) 1900–1903 1901
4 ◦C. After washing with PBST, the T-NEE was incubated for 60min
with the monoclonal antibody CB-11, diluted 1:5000 in PBST-milk.
After washing again with PBST, the T-NEEwas treated for 60min in
10ml of a 1:10,000 dilution of an anti-mouse HRP-conjugated anti-
body in PBST-milk. After ﬁnal washing, the T-NEE was dipped in a
three-electrode electrochemical cell containing 0.1mMMB, 10mM
phosphate buffer, pH 7, deaeratedwith nitrogen. The activity of the
immobilized HRP label was measured by CVs recorded at 50mV/s
in the absence and presence of 1.5mM H2O2. All measurements
were made as duplicate; precision was within 5%.
T-NEEs used as negative controls were not incubated with the
cell lysate, orwith lysates not containingHER2, and after the immo-
bilization of trastuzumab, they were incubated with the CB-11
antibody and the secondary labelled antibody.
2.4. Samples
HER-2 overexpressing (SKBR3) and HER2 negative (MCF7) cell
lysates were prepared using a lysis buffer (50mM Tris–Cl pH 8.0,
0.4M NaCl, 1% v/v, NP40, protease inhibitors), total proteins con-
centration was calculated and adjusted to 10g/l following a
Bradford assay. HER2 concentration was estimated 2ng/l by aFig. 1. Cyclic voltammograms recorded at a gold-NEE in 0.1mM methylene blue
before (dotted line) and after the addition of 1.2mM H2O2 (broken line) and
0.18mg/mL horseradish peroxidase (full line). Scan rate: 100mV/s, supporting elec-
trolyte 10mM phosphate buffer, pH 7.
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, at a N
tion c
secoFig. 2. Cyclic voltammograms recorded at 50mV/s in 10mMphosphate buffer, pH 7
negative) plus primary and secondary antibody with HRP label and dipped in solu
(dotted line). (B) Incubated in a 1:10 cell lysate containing HER2 plus primary and
(dashed line) and 1.5mM (dotted line).
The broken line in Fig. 1, shows that, by adding only H2O2,
no signiﬁcant change in the CV is detected. Finally, when also
the HRP is added (full line), dramatic changes become evident,
namely:• the reduction current increases and the voltammetric pattern
tends to a sigmoid;
• the reoxidation peak tends to disappear.
Both effects increase by increasing H2O2 concentration (not
shown). This agrees with the following reactions:
HRPred +H2O2 +2H+ → HRPox +2H2O (2)
HRPox + LB → HRPred +MB (3)
which, combinedwith reaction (1), give a complete electrocatalytic
cycle.
In order to test the capability of trastuzumab to act as capture
agent, preliminary immunoprecipitation assays were performed.
As negative control, we immunoprecipitated our sample using an
anti-PCNA (Proliferating cell nuclear antigen, Santa Cruz Biotech-
nology, CA) antibody, while as positive control, 70g of whole
SKBR3 (Pasleau et al., 1993) lysate were loaded onto the gel.
Western blot analysis performed after the immunoprecipitation,
evidenced the bands at 185 and 95kDa, both due to the HER2
protein, so conﬁrming (Molina et al., 2001) the efﬁciency of
Fig. 3. Dependence of the electrocatalytic current increments on the total protein conten
1:50. (B) Lysate of a HER2 overexpressing cancer undiluted and diluted 1:10.EE functionalizedwith trastuzumab. (A) Incubated in a 1:10MCF7 cell lysate (HER2
ontaining 0.1mM methylene blue without (full line) and with 1.5mM H2O2 added
ndary antibody with HRP label, in the presence of H2O2: 0mM (full line), 0.5mM
trastuzumab as capture agent in vitro. This prompted us to undergo
the study of trastuzumab functionalized NEEs.
Fig. 2A, shows the CV for MB at a NEE after the immobiliza-
tion of trastuzumab, recorded in the presence of a MCF7 cell lysate
(Her2 negative), primary and secondary labelled antibody, with
(dotted line) and without (full line) added H2O2 (namely, 1.5mM).
The two curves are essentially overlapped, and compare well with
the voltammetric signal recorded at bare NEEs. This conﬁrms that
no change in the voltammetric behavior of MB at the gold NEE is
caused by functionalization with trastuzumab. This agrees with
recent reports (Moulton et al., 2003) showing almost negligible
adsorption on gold of proteins with high isoelectric point, such as
trastuzumab, with a pI of 9.2 (Wiig et al., 2005). Moreover, no spe-
ciﬁc adsorptionofprimaryand labelledantibodyoccurs if the target
protein (HER2) is not present in the sample.
Fig. 2B shows the results after incubation in the cell lysates,
containing the target protein HER2, and incubation with the pri-
mary antibody and secondary antibodywith HRP label. The sample
was diluted 1:10 (total protein concentration 1g/l) and the
three CVs were recorded at three different H2O2 concentrations
(0, 0.5 and 1.5mM). The CV with no added H2O2 (full line in
Fig. 2B) is characterized by a larger peak-to-peak separation than
those in Fig. 2A, however the peak current ratio is still close
to unity. The immobilization of the all four-protein chain (spe-
ciﬁc antibody, target protein, primary antibody and secondary
labelled antibody) hinders slightly, but does not block electron
t (i) in 1.5mM H2O2 for T-NEEs treated as in Fig. 2B: (A) samples diluted 1:5, 1:10,
d Bioe
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transfer at the nanoelectrodes. The voltammogram recorded in
the presence of 1.5mM H2O2 (dotted line in Fig. 2B) shows a
typical electrocatalytic character. This H2O2 concentration gives
the highest electrocatalytic increase in currents, without caus-
ing any undesired increase in background current, as observed
for instance when 3 or 5mM H2O2 was added to the sample.
As shown by the plots in Fig. 3A, the electrocatalytic increase of
reduction currents (i) scales inversely with the dilution of the
lysate.
The results obtained with undiluted lysates put in evidence
some distortion of the CVs (not shown); this was probably due to
adsorption of proteins which are present at high concentration in
undiluted samples.
Note that the sensitivity of classical immunochemical assays,
such as Western blotting, is not high enough to detect the HER2
analyte in 1:10 or 1:50 diluted samples, while good electrocat-
alytic signals were detected with the T-NEE, speciﬁcally in the
most diluted samples examined here, where the HER2 concentra-
tion was approximately 0.04ng/l. In principle, detection limits at
NEEs can be further lowered by pulsed voltammetry (Moretto et
al., 2004). These encouraging results prompted us to test a pre-
liminary real application, that is the analysis of a breast cancer
lysate.
To this aim, T-NEEs were incubated in 4g/l lysates of a HER2
overexpressing cancer, both undiluted and diluted 1:10. Relevant
voltammetric patterns are characterized by signiﬁcant electrocat-
alytic effects both for the undiluted and diluted samples, with a
trend in the increase in electrocatalytic current opposite to thedilu-
tion of the sample (Fig. 3B). Useful signals are obtained also for the
1:10 diluted sample, where HER2 concentration is approximately
0.1ng/l.
These results conﬁrm, for the ﬁrst time, the high potentialities
of nanoelectrode ensembles as detection platforms for electro-
chemical immunosensors, where the recognition and detections
elements are separated, albeit strictly integrated within a range of
few nanometers.
4. Conclusions
This is, up to now, the ﬁrst report demonstrating the usefulness
of NEE as detection platforms for immunosensors where the high
signal/background ratio typical of nanoelectrodes is preserved. This
is particularly attractive for detection of trace proteins such as
HER2. T-NEEs detect the target protein in diluted samples, where
traditional immunochemical methods, such as Western blotting,
fail. Specialized studies for quantifying the analytical performances
of T-NEEs (detection limit, dynamic range, etc.) are in progress. Thelectronics 23 (2008) 1900–1903 1903
applicability of this approach to other antibodies was tested with
preliminarily successful experiments (Pozzi Mucelli, 2007) with
respect to the detection of single chain fragment variable (Sblattero
and Bradbury, 2000). A ﬁnal note concerns with the possible pho-
toactivation of polycarbonate which could increase the loading of
the capture antibody (Bora et al., 2006), so improving further the
detection capabilities.
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